Jiangsu Hengrui Medicine Co., Ltd.
Clinical trials sponsored by Jiangsu Hengrui Medicine Co., Ltd., explained in plain language.
-
New hope for tough pancreatic cancer: targeted drug combo enters final testing phase
Disease control Not yet recruitingThis Phase 3 trial is testing whether adding the experimental drug HRS-4642 to standard chemotherapy can help people with advanced pancreatic cancer that has a specific genetic change (KRAS G12D). About 588 participants will be randomly assigned to receive either the drug combo o…
Phase: PHASE3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Healthy volunteers to test new formulation of breast cancer drug HRS-6209
Knowledge-focused Not yet recruitingThis early-stage trial will test two different versions of the experimental drug HRS-6209 in 21 healthy Chinese adults. The goal is to see how the body absorbs the old and new capsule forms, and whether a high-fat meal affects absorption. No treatment benefit is expected for part…
Phase: PHASE1 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC